Press Releases
– In vitro studies indicate IGM-6268 exhibits potent neutralization activity against the Omicron variant and all other Variants of Concern and Variants of Interest tested – – IGM-6268 Phase 1 clinical trials advancing in U.S. and South Africa – Excerpt from the Press Release: MOUNTAIN VIEW, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq:…
Read More
Excerpt from the Press Release: MARLBOROUGH, Mass. & PRINCETON, N.J.–(BUSINESS WIRE)–Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in SEP380-301, a Phase 3 clinical study evaluating non-racemic amisulpride (SEP-4199) for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression). Non-racemic amisulpride…
Read More
– Two studies evaluate ARD-101 in Obesity: one in General Obesity and the other in Refractory Weight Gain Post-Bariatric Surgery – The 3rd clinical trial is in Prader-Willi Syndrome, a rare genetic disorder characterized by persistent hyperphagia Excerpt from the Press Release: SAN DIEGO, Feb. 2, 2022 /PRNewswire/ — Aardvark Therapeutics, Inc., a clinical stage biopharmaceutical company focused…
Read More
Excerpt from the Press Release: Independent safety review completed with no toxicity concerns Cohort builds on prior proof-of-concept data demonstrating clinical benefit of pelareorep-checkpoint inhibitor combination in pancreatic cancer Multi-indication trial being conducted in collaboration with Roche and AIO also includes cohorts in metastatic colorectal and advanced anal cancers SAN DIEGO and CALGARY, AB, Feb. 2, 2022 /PRNewswire/ — Oncolytics…
Read More
— ENVISION Study Design Similar to Successful UGN-102 Phase 2b OPTIMA II Trial — Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced the initiation of its Phase 3 ENVISION study of UGN-102 (mitomycin)…
Read More
Excerpt from the Press Release: ZUG, Switzerland, and CAMBRIDGE, Mass., and SAN DIEGO, Calif., February 2, 2022 – CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, today…
Read More
CARLSBAD, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), today announced that its Investigational New Drug (IND) application for PBI-0451 has been cleared…
Read More
Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Synthekine Inc., an engineered cytokine therapeutics company, today announced the dosing of the first patient in a Phase 1a/1b clinical trial of its IL-2 partial agonist, STK-012, for the treatment of solid tumors. STK-012 is designed as an alpha/beta-biased IL-2 partial agonist to selectively stimulate antigen-activated T…
Read More
– Over 900 patients with diabetic macular edema enrolled worldwide Excerpt from the Press Release: PALO ALTO, Calif., Feb. 3, 2022 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has completed enrollment in its GLEAM and GLIMMER Phase 3…
Read More
–The method could eventually lead to more personalized medicine approaches as well as properly diagnose patients with multiple disorders — Excerpt from the Press Release: PHILADELPHIA, Feb. 1, 2022 /PRNewswire/ –Minority populations have been historically under-represented in existing studies addressing how genetic variations may contribute to a variety of disorders. A new study from researchers at Children’s Hospital…
Read More